Skip to content

Pharminent

cropped-ChatGPT-Image-Jun-22-2026-05_46_48-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Policy / Pricing
  • The next FDA commissioner must be a champion for gene therapies
  • Policy / Pricing

The next FDA commissioner must be a champion for gene therapies

BioSpace

The FDA must provide consistent and predictable regulatory frameworks if the U.S.

Gene Therapy Platform

Read full story

pharminent June 5, 2026 (Last updated: June 5, 2026)

BioSpace

The FDA must provide consistent and predictable regulatory frameworks if the U.S.

Gene Therapy Platform

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Otsuka energizes IgA neuropathy space with new Phase 3 Voyxact data
Next: Medicare Advantage in 2026: Enrollment Update and Key Trends

Related Stories

  • Policy / Pricing

EFPIA report adds to pressures on EU drug pricing policy

pharminent June 24, 2026
  • Policy / Pricing

US launches probe of German ‘underpayment’ for medicines

pharminent June 19, 2026
  • Policy / Pricing

FDA’s new voucher program hints at broader policy agenda, making many ‘uncomfortable’

pharminent June 19, 2026

You May Have Missed

  • News

Lilly Medicare GLP-1 Bridge Launches July 1 With Foundayo and Zepbound

pharminent June 26, 2026
  • News

Moderna Maps R&D ‘Horizons’ as 2028 Break-Even Goal Looms

pharminent June 26, 2026
  • Regulatory

Replimune gets early August decision date for twice-rejected melanoma drug

pharminent June 26, 2026
  • Pipeline

Moderna looks out to R&D ‘horizons’ as 2028 break-even goal looms

pharminent June 26, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.